Illumina

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."

The partners will codevelop software for both small and large variant detection and Illumina will create hardware-accelerated versions for its Dragen platform.

The firm disclosed to the state of California that it plans to lay off 42 employees in San Diego and 16 employees in Foster City.

Under the amended agreement, Illumina will pay PacBio $6 million each month until the end of this year and more if the deal is extended into 2020.

Using 350 human genomes from different populations, the two centers plan to develop a multi-genome reference sequence that is as complete as possible.

Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.

Get the latest news from Illumina, TRC, Diagnomics, Danaher, BioDiscovery and Abbot for the week of 9/13/19